论文部分内容阅读
The enzyme, dipeptidyl peptidase Ⅳ(DPP Ⅳ), is a novel target for the treatment of type 2 diabetes. Dipeptidyl peptidase Ⅳ inhibition improves the impaired insulin secretion and decrease postprandial concentrations of glucagon by enhancing the incretin hormone levels lucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide(GIP). Recently, DPP Ⅳ inhibitors have attracted more and more attention, several of which have entered pre-clinical and clinical trials, and one has received approval for use as an anti-diabetic agent. Among the DPP Ⅳ inhibitors, two leading agents(sitagliptin and vildagliptin) have been shown to be effective in reducing glycosylated hemoglobin(HbA1c) and fasting plasma glucose(FPG) in patients with type 2 diabetes. This review summarizes the evidence supporting DPP IV inhibitors as potential antidiabetic agents.
The enzyme, dipeptidyl peptidase IV (DPP IV), is a novel target for the treatment of type 2 diabetes. Dipeptidyl peptidase IV inhibition improves the impaired insulin secretion and decrease postprandial concentrations of glucagon by enhancing the incretin hormone levels lucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide / gastric inhibitory polypeptide (GIP). Recently, DPP IV inhibitors have attracted more and more attention, several of which have entered pre-clinical and clinical trials, and one has received approval for use Among the DPP IV inhibitors, two leading agents (sitagliptin and vildagliptin) have been shown to be effective in reducing glycosylated hemoglobin (HbA1c) and fasting plasma glucose (FPG) in patients with type 2 diabetes. This review summarizes the evidence supporting DPP IV inhibitors as potential antidiabetic agents.